2. Academic Validation
  3. Preparation of Novel PARP1 Inhibitors and Their Use in Cancer Treatment

Preparation of Novel PARP1 Inhibitors and Their Use in Cancer Treatment

  • ACS Med Chem Lett. 2025 Jul 23;16(8):1494-1496. doi: 10.1021/acsmedchemlett.5c00411.
Xin Zhou 1,  Steven H Liang 1
Affiliations

Affiliation

  • 1 Department of Radiology and Imaging Sciences, Emory University, 1364 Clifton Road, Atlanta, Georgia 30322, United States.
PMID: 40832518 DOI: 10.1021/acsmedchemlett.5c00411
Abstract

Poly-(ADP-ribose) polymerase 1 (PARP1) is the most widely studied PARP enzyme, which plays a significant role in DNA damage repair. PARP1 inhibition has emerged as a clinically validated strategy to selectively target two Cancer subtypes: tumors with homologous recombination deficiency (HRD) and Epstein-Barr virus (EBV)-associated malignancies. This patent highlights the synthesis and pharmaceutical compositions of PARP1 inhibitors and their uses in the treatment of Cancer.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-175471
    PARP1 抑制剂
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z